Trial Information

Summary: Randomized, Multicenter, Open Label, Phase IV Study Evaluating the Efficacy and Safety of 16-Week Versus 24-Week Treatment with PEGASYS in Combination with Copegus in Interferon-naïve Patients with Chronic Hepatitis C Genotype 2 or 3 Virus Infection

Stanford University is looking for volunteers 18 years or older with chronic hepatitis C (genotype 2 or 3) who have never received prior antiviral treatment for hepatitis C infection (e.g., interferon, ribavirin). This study will compare dosing regimens of drug Pegasys in combination with Copegus.

The study provides free study-related physical exams, medications and diagnostic tests. Pegasys is administered by self-injection. Ability to come to Stanford area for multiple, regular visits is also required. Subjects must meet study criteria in order to participate.

Volunteers with chronic hepatitis C who are interested in participation in this study directed by Emmet Keeffe, MD, Professor of Medicine, Stanford University, should contact the liver research office @ (650) 724-7057.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 1, 2008 at 5:43:56 AM